Biotech industry prospers in Nansha

Guangzhou's Nansha district is currently home to more than 210 life science companies, and it has been pushing forward the construction of major industrial platforms such as the national health tourism demonstration base, local media outlets reported on May 7.

More and more high-quality resources are now clustering in Nansha, and an industrial base for precision medicine in the Guangdong-Hong Kong-Macao Greater Bay Area has now settled down in the district.

EdiGene's clinical application center in Nansha announced in January that its clinical trial application of a gene editing therapy product for transfusion-dependent β-thalassemia has gained approval from the National Medical Products Administration.

The New Horizon Health operation center in the Greater Bay Area has already started operation and the center is expected to be able to provide nearly 500,000 cancer screenings and testing services for people all over China.

In addition, Ming Med Biotech has finished its A-round funding of $60 million.

Officials from Nansha's bureau of financial affairs noted that a better business environment will be created for local companies to facilitate further development.